RxDoctor Payments Data

Erin Katz, MD

Urology · Corona, CANPI 1447296090

Payments from drug & device makers

$158,000in general payments, 2019–2025

Across 230 payments — averaging $686.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bluewind Medical$153K
  • Neotract Inc.$1K
  • Caldera Medical, Inc$678
  • Teleflex LLC$561
  • AbbVie$278
  • Boston Scientific$273
  • plus $2K from 17 others

What the payments were for

  • Travel & lodging$1,97433%
  • Food & beverage$3,89664%
  • Education$751%
  • Gifts$1162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$158,000 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$151,708
Medicare patients
350
Services billed
8,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron175$105,725
ElmironPentosan Polysulfate Sodium14$17,801
Tolterodine Tartrate ErTolterodine Tartrate183$14,245
Methenamine Hippurate178$9,687
EstringEstradiol11$5,941
Mirabegron ErMirabegron14$5,820
Tamsulosin Hcl262$5,240
Fesoterodine Fumarate ErFesoterodine Fumarate90$4,309
Solifenacin Succinate128$4,289
Estradiol37$2,654
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst235$2,441
NitrofurantoinNitrofurantoin Macrocrystal127$2,368
Trospium Chloride38$1,894
Testosterone25$1,810
Oxybutynin Chloride ErOxybutynin Chloride104$1,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$266$105,725175 claims
PfizerEstring$148$5,94111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,324 urology providers in California.

Other urology in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →